GalaxyBiomedical Investment

Overview

GalaxyBiomedical Investment was established in 1993 in Beihai, China, as a subsidiary of YH Group. Chairman Keyang Liu leads the firm, with co-founder Huang Jian having previously served as Chairman and Legal Representative. The firm's corporate structure ties its fortunes to the operating performance of its core biomedical holdings while leaving room for opportunistic diversification into industrial and real-asset categories. Portfolio companies include Nanjing Galaxy Biotechnology and Suzhou Galaxy Biomedical, which anchor a biopharma vertical focused on China's domestic market. Beyond biomedicine, the firm holds interests in distribution equipment and electronic components. A notable non-healthcare asset is the Galaxy Software Technology Park, a commercial real estate project on Xizang Road in Beihai. The firm draws on tight operational relationships with Beijing Teamsun Technology — linked through shared directorships — and with the China Venture Capital Research Institute, where executives serve on the East China Representative Office. Through subsidiary Liuzhou Special Transformer, GalaxyBiomedical holds a director-unit seat within the Transformer Branch of the China Electricity Industry Association, signaling a meaningful industrial manufacturing tilt. The firm's geographic footprint is concentrated in China's southern corridor, with headquarters in Beihai, operating entities in Nanjing and Suzhou, and a manufacturing presence in Liuzhou. No publicly disclosed AUM or deployment figures exist, which is characteristic of a holding company that measures itself by subsidiary revenue rather than third-party capital. The firm's structural identity is its operating-company DNA: it is not a pure financial allocator but a parent with direct control over subsidiaries that generate cash flows for reinvestment. This creates a permanent-capital base and a decision-making timeline that ignores fund cycles. Succession appears to rest with Keyang Liu, who holds both the Chairmanship and Board Secretary role, concentrating governance in a single executive.